vitamin
import
regul
calcium
bone
homeostasi
also
involv
regul
differ
gene
cellular
function
particularli
context
fl
ammat
regener
immun
control
convers
vitamin
de
fi
cienci
often
found
chronic
infecti
fl
ammatori
diseas
thought
drive
enhanc
uncontrol
fl
ammat
chronic
obstruct
pulmonari
diseas
copd
character
chronic
fl
ammat
airway
often
cigarett
smoke
recogn
repetit
airway
infect
system
consequ
comorbid
also
contribut
progress
natur
copd
vitamin
de
fi
cienci
known
sneak
earli
stage
copd
becom
highli
preval
sever
stage
may
therebi
catalys
airway
infect
fl
ammat
system
consequ
undoubtedli
vitamin
de
fi
cienci
enhanc
bone
resorpt
osteoporosi
copd
appropri
vitamin
supplement
recommend
howev
con
fl
ict
evid
emerg
extracalcem
effect
vitamin
copd
recent
intervent
trial
highdos
supplement
copd
abl
reduc
exacerb
frequenc
subgroup
patient
lowest
baselin
vitamin
level
con
fi
rm
sever
vitamin
de
fi
cienci
health
hazard
clinic
experiment
studi
need
explor
last
year
increas
interest
role
vitamin
vitamin
de
fi
cienci
variou
chronic
diseas
besid
wellknown
effect
vitamin
de
fi
cienci
bone
loss
adult
accumul
evid
also
link
low
vitamin
nutrit
statu
highli
preval
chronic
ill
includ
cancer
autoimmun
diseas
infecti
cardiovascular
diseas
vitamin
known
import
fl
uenc
immunoregul
express
antimicrobi
peptid
sinc
patient
chronic
obstruct
pulmonari
diseas
copd
often
integr
comorbid
diseas
one
given
copd
exacerb
trigger
bacteri
viral
infect
vitamin
could
play
key
role
pathogenesi
diseas
chapter
aim
discuss
preval
determin
vitamin
de
fi
cienci
copd
wellknown
effect
vitamin
develop
treatment
copdassoci
osteoporosi
potenti
role
uncontrol
fl
ammatori
cascad
system
consequ
diseas
copd
chronic
diseas
character
air
fl
ow
limit
progress
fulli
revers
associ
abnorm
fl
ammatori
respons
lung
noxiou
particl
gase
western
countri
tobacco
smoke
major
caus
copd
account
case
sinc
smoker
develop
sever
copd
factor
biolog
hereditari
environment
must
involv
narrow
airway
fl
ammat
mucu
product
irrevers
remodel
emphysema
result
limit
expiratori
air
fl
ow
disturb
ga
exchang
current
estim
million
peopl
suffer
copd
worldwid
number
still
increas
world
health
organ
predict
copd
rise
sixth
third
lead
caus
death
next
cardiovascular
diseas
cancer
accord
global
obstruct
lung
diseas
gold
de
fi
nition
diagnosi
copd
base
spirometri
measur
postbronchodil
forc
expiratori
volum
forc
vital
capac
ratio
fev
fvc
subsequ
copd
categor
differ
stage
sever
gold
stage
go
mild
moder
sever
sever
diseas
accord
fev
note
howev
major
copd
patient
especi
earli
stage
diseas
report
complaint
perform
spirometri
thu
unawar
diseas
treatment
copd
focus
minim
symptom
prevent
exacerb
except
smoke
cessat
far
treatment
clearli
proven
signi
fi
cantli
modifi
copd
diseas
progress
recent
data
howev
indic
pharmacolog
intervent
inhal
therapi
may
slow
yearli
declin
fev
pathophysiolog
copd
character
increas
fl
ammatori
respons
airway
parenchyma
besid
increas
number
neutrophil
macrophag
tlymphocyt
copd
associ
elev
concentr
variou
cytokin
includ
interleukin
tumour
necrosi
factor
alpha
tnfa
oxid
stress
releas
proteolyt
enzym
cigarett
smoke
known
caus
direct
injuri
airway
epitheli
cell
lead
releas
endogen
intracellular
molecul
dangerassoci
molecular
pattern
damp
signal
recogn
tolllik
receptor
epitheli
cell
initi
nonspeci
fi
c
fl
ammatori
respons
reaction
releas
earli
cytokin
tnfa
macrophag
neutrophil
dendrit
cell
recruit
site
fl
ammat
proteolyt
enzym
reactiv
oxygen
speci
releas
may
caus
damag
lung
next
selfantigen
antigen
come
pathogen
bound
dendrit
cell
activ
naiv
cell
cell
may
lead
antibodi
produc
b
cell
adapt
immun
respons
may
enhanc
fl
ammatori
cascad
addit
observ
reduct
regulatori
cell
treg
copd
lung
rise
proin
fl
ammatori
cell
point
toward
impair
immun
regul
copd
macrophag
believ
play
central
role
pathophysiolog
copd
import
sourc
proin
fl
ammatori
mediat
may
also
protect
infect
phagocytosi
copd
alveolar
macrophag
appear
resist
antiin
fl
ammatori
effect
corticosteroid
reduc
activ
histon
deacetylas
nuclear
enzym
switch
fl
ammatori
gene
activ
nuclear
factor
nfk
b
addit
taylor
colleagu
recent
demonstr
phagocytot
capac
macrophag
copd
patient
impair
may
lead
bacteri
colon
increas
exacerb
frequenc
overal
complex
pathogenesi
copd
differ
mechan
risk
factor
fl
ect
broad
variat
clinic
phenotyp
progress
diseas
mark
declin
forc
expiratori
volum
fev
copd
patient
becom
prone
exacerb
exacerb
copd
acut
worsen
respiratori
symptom
associ
increas
symptom
worsen
lung
function
recent
studi
shown
qualiti
life
health
statu
patient
mainli
determin
presenc
frequenc
exacerb
turn
may
lead
faster
declin
fev
although
viral
bacteri
infect
assum
major
caus
exacerb
factor
includ
environment
pollut
allergen
also
identi
fi
ed
exact
role
bacteri
infect
copd
exacerb
often
bias
bacteri
colon
airway
stabl
state
organ
isol
exacerb
haemophilu
fl
uenza
streptococcu
pneumonia
moraxella
catarrhali
staphylococcu
aureu
pseudomona
aeruginosa
differ
studi
shown
preval
load
organ
increas
exacerb
recent
evid
indic
acquisit
new
bacteri
strain
like
main
trigger
exacerb
besid
bacteri
infect
exacerb
may
also
trigger
viral
infect
includ
infect
rhinovirus
coronaviru
respiratori
syncyti
viru
fl
uenza
parain
fl
uenza
adenoviru
moreov
recent
frequent
exacerb
phenotyp
identi
fi
ed
suggest
innat
adapt
immun
defenc
host
also
contribut
exacerb
suscept
individu
therapi
may
becom
import
nearbi
futur
copd
restrict
lung
also
associ
system
fl
ammat
increas
comorbid
consid
import
target
therapeut
approach
copd
increas
system
level
tnfa
creactiv
protein
crp
commonli
found
patient
copd
common
comorbid
copd
includ
lung
cancer
cardiovascular
diseas
osteoporosi
diabet
skelet
muscl
dysfunct
whether
comorbid
caus
underli
diseas
coexist
common
risk
factor
smoke
age
inact
far
understood
like
mechan
play
togeth
attract
hypothesi
fl
ammat
lung
spill
system
circul
affect
organ
corrobor
idea
whatev
mechan
may
presenc
comorbid
clearli
contribut
poor
outcom
copd
vitamin
gener
obtain
photosynthesi
skin
also
deriv
nutrit
fatti
fi
sh
fi
sh
liver
oil
dairi
product
ultraviolet
light
catalys
fi
rst
step
vitamin
biosynthesi
convers
previtamin
next
step
hydroxyl
liver
circul
serum
long
halflif
day
next
hydroxyl
activ
vitamin
metabolit
oh
ahydroxylas
kidney
control
serum
level
calcium
phosphat
regul
hormon
parathyroid
hormon
pth
calcitonin
phosphatonin
oh
also
induc
express
catabol
oh
biolog
inact
watersolubl
metabolit
therebi
serv
neg
feedback
major
oh
bound
plasma
protein
vitamin
bind
protein
dbp
carri
deliveri
respect
target
organ
oh
may
thu
bind
nuclear
vitamin
receptor
vdr
intestin
bone
kidney
parathyroid
gland
cell
result
mainten
normal
serum
calcium
phosphoru
level
relat
effect
miner
turnov
bone
sinc
hydroxylas
nuclear
receptor
vdr
wide
present
cell
sever
extraren
tissu
skin
bone
prostat
immun
cell
local
oh
concentr
also
exert
differ
autocrin
paracrin
function
although
enzym
found
ident
one
express
kidney
express
regul
immun
signal
instead
mediat
bone
calcium
homeostasi
oh
mediat
effect
bind
nuclear
vdr
vitaminvdr
complex
may
activ
vitamin
respons
element
vdre
gene
involv
differ
cellular
process
estim
mousehuman
genom
regul
vitamin
directli
indirectli
vitamin
control
mani
gene
involv
regul
cellular
prolifer
differenti
apoptosi
healthi
patholog
cell
long
halflif
typic
use
determin
vitamin
statu
fl
ect
vitamin
synthes
skin
well
acquir
diet
vitamin
degrad
catabol
enzym
focus
calcem
effect
vitamin
insuf
fi
cienci
best
de
fi
ned
level
ngml
nmoll
sensit
paramet
determin
vitamin
de
fi
cienci
serum
level
pth
older
data
clearli
demonstr
level
ngml
associ
increas
pth
express
base
observ
studi
sever
expert
suggest
noncalcem
effect
serum
level
least
ngml
nmoll
requir
far
intervent
studi
support
lack
dietari
sourc
vitamin
limit
food
forti
fi
cation
mostli
inadequ
nonexist
although
sunlight
import
sourc
vitamin
sever
factor
fl
uenc
amount
vitamin
synthes
season
latitud
cloth
use
sunscreen
darker
skin
pigment
age
exampl
age
associ
decreas
concentr
skin
therebi
reduc
capac
synthes
vitamin
even
regularli
expos
sunlight
elderli
peopl
produc
less
cutan
vitamin
compar
young
adult
due
cultur
habit
cloth
even
live
sunni
climat
commonli
found
de
fi
cient
vitamin
data
third
nation
health
nutrit
examin
survey
nhane
iii
reveal
us
adult
white
popul
african
american
level
vitamin
least
ngml
accord
current
de
fi
nition
estim
one
billion
peopl
worldwid
impair
serum
level
vitamin
current
supplement
regimen
daili
dose
iu
vitamin
restor
de
fi
cient
serum
level
gener
adult
popul
concentr
ngml
higher
dose
probabl
requir
increas
level
even
higher
level
may
need
noncalcem
diseas
popul
risk
present
specul
ideal
target
rang
level
maxim
exploit
extracalcem
effect
also
acknowledg
extens
expert
analysi
potenti
effect
vitamin
supplement
health
outcom
northamerican
subject
conclud
present
insuf
fi
cient
evid
extraskelet
bene
fi
ts
vitamin
therapi
new
random
control
trial
abl
de
fi
ne
effect
copd
patient
consid
high
risk
becom
vitamin
de
fi
cient
varieti
reason
lower
food
intak
reduc
capac
vitamin
synthesi
skin
age
smoke
absenc
outdoor
activ
sun
exposur
impair
activ
renal
dysfunct
lower
storag
capac
muscl
fat
wast
may
contribut
defect
vitamin
statu
copd
black
colleagu
examin
spirometr
data
third
nation
health
nutrit
examin
survey
crosssect
survey
us
civilian
year
age
discov
import
link
vitamin
spirometr
data
adjust
potenti
confound
strong
relationship
serum
level
pulmonari
function
assess
fev
fvc
found
although
signi
fi
cant
correl
airway
obstruct
could
found
observ
doserespons
relationship
suggest
causal
link
observ
smoke
africanamerican
rapidli
develop
sever
air
fl
ow
obstruct
compar
caucasian
also
agreement
idea
presum
lower
vitamin
statu
africanamerican
correl
increas
suscept
copd
furthermor
differ
genet
variant
involv
vitamin
signal
pathway
shown
determin
level
variant
repeatedli
associ
copd
instanc
variant
dbp
gene
gc
shown
protect
risk
factor
copd
recent
robust
candid
gene
studi
two
larg
data
set
identi
fi
ed
gc
gene
suscept
loci
copd
studi
forli
colleagu
vitamin
de
fi
cienci
ngml
found
cohort
wait
lung
transplant
fail
compar
vitamin
serum
level
match
control
group
howev
recent
demonstr
group
smoke
individu
patient
copd
like
suffer
vitamin
de
fi
cienci
age
gendermatch
healthi
control
smoker
without
copd
copd
patient
found
signi
fi
cant
associ
vitamin
serum
level
sever
diseas
assess
fev
preval
vitamin
de
fi
cienci
de
fi
ned
level
ngml
increas
respect
sever
gold
sever
copd
patient
gold
fig
interestingli
also
show
level
determin
genet
variant
vitamin
bind
gene
gc
correct
age
gender
smoke
histori
diseas
sever
homozyg
carrier
allel
lowest
vitamin
level
exhibit
increas
risk
copd
although
risk
effect
certain
gc
allel
may
relat
lower
bioavail
vitamin
author
suggest
protein
variant
dbp
may
directli
affect
fl
ammat
airway
wood
colleagu
instanc
demonstr
local
dbp
express
sputum
copd
patient
correl
macrophag
phagocytosi
capac
suggest
risk
effect
dbp
may
found
differ
activ
macrophag
recent
popul
base
studi
individu
live
hertfordshir
uk
found
reduc
vitamin
intak
copd
subgroup
individu
compar
noncopd
subject
abl
con
fi
rm
posit
associ
serum
level
fev
fvc
surprisingli
shaheen
et
al
found
patient
highest
vitamin
level
like
copd
conclud
contrast
prudent
dietari
pattern
intak
high
amount
antioxid
vitamin
import
determin
adult
pulmonari
function
risk
copd
unfortun
popul
take
dietari
vitamin
supplement
unspeci
fi
ed
reason
may
affect
analysi
bias
conclus
final
small
substudi
lung
health
studi
iii
conduct
select
individu
mean
level
copd
patient
rapid
fev
declin
found
similar
mean
level
patient
slow
declin
suggest
vitamin
de
fi
cienci
contribut
copd
progress
togeth
con
fl
ict
data
clear
prospect
studi
need
determin
causal
relationship
vitamin
de
fi
cienci
pulmonari
function
copd
even
causal
found
pulmonari
function
variabl
vitamin
de
fi
cienci
may
still
alter
diseas
cours
affect
outcom
respiratori
tract
infect
comorbid
low
level
vitamin
result
low
bioavail
calcium
stimul
parathyroid
gland
increas
secret
pth
kidney
pth
reduc
reabsorpt
phosphat
proxim
tubul
increas
calcium
reabsorpt
distal
tubul
result
net
increas
calciumphosph
ratio
pth
also
induc
renal
hydroxylas
express
lead
increas
product
activ
oh
oh
enhanc
intestin
calcium
absorpt
act
immatur
osteoblast
cell
stimul
osteoclastogenesi
ranklrank
regulatori
system
enhanc
bone
resorpt
mobil
calcium
bone
compart
caus
osteopenia
osteoporosi
increas
risk
bone
fractur
result
higher
level
calcium
oh
neg
feedback
pth
subsequ
limit
bone
resorpt
osteoporosi
skelet
disord
character
compromis
bone
strength
result
higher
suscept
fractur
bone
strength
determin
structur
qualiti
bone
bone
miner
densiti
latter
measur
dual
xray
absorptiometri
dxa
use
de
fi
ne
osteoporosi
osteoporosi
major
health
problem
osteoporot
fractur
frequent
caus
signi
fi
cant
longlast
morbid
older
individu
hip
fractur
type
nonvertebr
fractur
account
burden
osteoporosi
increas
mortal
function
declin
loss
qualiti
life
need
institution
femal
gender
advanc
age
histori
fragil
fractur
current
former
smoke
low
bodi
weight
weight
loss
use
system
glucocorticoid
wellestablish
risk
factor
osteoporosi
osteoporot
fractur
mani
risk
factor
present
copd
patient
especi
sever
stage
surpris
osteoporosi
copd
strongli
link
recent
review
graatverboom
et
al
con
fi
rmed
low
bodi
mass
diseas
sever
use
corticosteroid
age
femal
gender
independ
risk
factor
osteoporosi
copd
major
studi
report
increas
risk
osteoporosi
decreas
fev
fig
preval
osteoporosi
copd
vari
depend
diagnost
method
use
popul
studi
sever
underli
respiratori
diseas
sin
colleagu
use
nhane
iii
data
demonstr
air
fl
ow
obstruct
independ
associ
reduc
bone
miner
densiti
populationbas
cohort
nonhispan
white
particip
women
sever
copd
osteoporosi
wherea
almost
women
mild
airway
obstruct
osteopenia
comparison
men
lower
risk
women
still
men
sever
copd
preval
osteoporosi
osteopenia
respect
approxim
three
time
higher
expect
studi
look
preval
osteoporosi
use
dexa
scan
measur
bone
miner
densiti
evalu
microarchitectur
chang
bone
known
microarchitectur
chang
may
equal
caus
fragil
fractur
even
normal
bone
densiti
therefor
consid
osteoporot
well
take
dexa
measur
vertebr
fragil
fractur
account
graatverboom
et
al
found
preval
osteoporosi
almost
doubl
copd
outpati
indic
preval
osteoporosi
copd
might
much
higher
current
preval
data
suggest
interest
relationship
also
found
emphysema
associ
reduc
bone
miner
densiti
lower
bodi
mass
index
may
repres
clinic
phenotyp
risk
osteoporosi
visual
emphysema
assess
ct
scan
found
independ
risk
factor
osteopeniaosteoporosi
differ
bone
turnov
marker
increas
copd
recent
data
also
show
osteoprotegerin
critic
involv
bone
turnov
block
rankrankl
interact
may
becom
use
marker
parenchym
lung
destruct
copd
current
known
whether
vitamin
pathway
involv
speci
fi
c
develop
emphysema
studi
laboratori
anim
certainli
corrobor
idea
consequ
osteoporot
fragil
fractur
copd
popul
may
detriment
hipfractur
patient
mortal
close
within
year
surviv
fractur
institution
function
consequ
exact
preval
hip
fractur
copd
patient
studi
detail
probabl
impact
event
disabl
copd
patient
even
wors
addit
vertebr
compress
fractur
lead
back
pain
function
impair
increas
kyphosi
reduc
rib
cage
mobil
declin
pulmonari
function
impact
loss
vertebr
height
pulmonari
deterior
copd
demonstr
leech
colleagu
found
vital
capac
total
lung
capac
increment
declin
number
thorac
vertebr
fractur
increas
eolo
studi
larg
copd
cohort
particip
one
vertebr
fractur
preval
signi
fi
cantli
correl
sever
diseas
kyphosi
relat
osteoporosi
may
also
caus
limit
rib
mobil
inspiratori
muscl
dysfunct
also
correl
loss
fev
fvc
doubt
vitamin
protect
osteoporosi
osteoporot
fractur
therefor
suf
fi
cient
vitamin
supplement
encourag
fact
major
copd
patient
older
age
mani
common
risk
factor
osteoporosi
like
de
fi
cient
vitamin
support
standard
supplement
especi
sever
stage
diseas
daili
dose
iu
vitamin
togeth
adequ
daili
calcium
intak
mg
probabl
best
strategi
prevent
fractur
older
subject
supplement
known
restor
low
serum
level
gener
adult
popul
concentr
ngml
nmoll
threshold
patient
copd
particularli
system
corticosteroid
also
consid
dexa
scan
need
osteoporosi
medic
even
though
causal
therapeut
bene
fi
ts
vitamin
remain
establish
pulmonari
fl
ammat
comorbid
prevent
vertebr
fractur
posit
affect
pulmonari
function
along
progress
loss
pulmonari
function
copd
patient
becom
prone
acut
copd
exacerb
import
caus
hospit
impair
qualiti
life
mortal
appropri
antimicrobi
treatment
essenti
treatment
acut
bacteri
exacerb
wherea
case
colon
repetit
longterm
antibiot
treatment
still
avoid
contribut
multiresist
colon
strain
antiin
fl
ammatori
treatment
differ
inhal
system
corticosteroid
current
valid
copd
reduc
exacerb
top
bronchodil
therapi
inhibitor
neomacrolid
promis
agent
perspect
seem
bene
fi
cial
subgroup
patient
repetit
exacerb
attract
altern
approach
might
upregul
innat
immun
defenc
system
vitamin
particularli
regard
antimicrobi
polypeptid
wang
colleagu
demonstr
differ
cell
type
epitheli
cell
white
blood
cell
gene
encod
antimicrobi
polypeptid
cathelicidin
b
defensin
driven
vdr
element
contain
promot
human
monocyt
tlr
activ
upregul
express
vdr
hydroxylas
gene
lead
induct
kill
intracellular
mycobacterium
tuberculosi
also
found
effect
kill
number
antibioticresist
strain
pseudomona
aureu
differ
virus
chlamydia
diffus
express
surfac
epithelia
human
airway
submucos
gland
macrophag
neutrophil
substitut
local
vitamin
insuf
fi
cienci
may
reduc
bacteri
load
concomit
airway
fl
ammat
apart
potenti
bene
fi
bacteri
erad
vitamin
may
also
downregul
complex
fl
ammatori
cascad
sever
level
vitro
vitamin
reduc
express
tlr
critic
induct
earli
immun
respons
high
level
vitamin
also
inhibit
dendrit
cell
matur
lower
express
mhc
class
ii
molecul
downregul
costimulatori
molecul
lower
product
proin
fl
ammatori
cytokin
ifng
sever
mous
model
vitamin
also
lead
switch
respons
toward
regulatori
cell
answer
low
serum
level
vitamin
also
correl
decreas
phagocyt
activ
macrophag
patient
ricket
wherea
antimicrobi
activ
macrophag
tuberculosi
could
increas
vitamin
supplement
overal
potenti
vitamin
reduc
proin
fl
ammatori
process
innat
adapt
immun
system
togeth
increas
bacteri
erad
self
antimicrobi
peptid
enhanc
macrophag
phagocytosi
may
offer
great
potenti
treatment
exacerb
indirect
clinic
evid
hypothesi
may
found
observ
exacerb
copd
common
winter
level
lowest
addit
data
nhane
iii
show
upper
respiratori
tract
infect
frequent
patient
lowest
vitamin
level
investig
intrigu
hypothesi
random
placebocontrol
intervent
trial
perform
evalu
effect
vitamin
supplement
copd
patient
prone
exacerb
one
hundr
eightytwo
patient
moder
sever
copd
histori
recent
exacerb
supplement
iu
vitamin
placebo
everi
week
one
year
highdos
supplement
mean
serum
level
increas
signi
fi
cantli
intervent
arm
reach
stabl
mean
serum
level
ngml
therapeut
rang
hypothes
extracalcem
effect
howev
despit
effect
supplement
signi
fi
cant
differ
time
fi
rst
exacerb
time
fi
rst
hospit
exacerb
rate
could
observ
intervent
control
group
absenc
therapeut
effect
vitamin
may
relat
fact
patient
present
sever
diseas
maxim
inhal
therapi
treatment
known
reduc
exacerb
like
addit
effect
vitamin
top
regular
treatment
dif
fi
cult
obtain
intervent
within
earli
copd
stage
take
less
medic
might
therefor
effect
line
idea
milder
stage
also
sensit
diseas
modi
fi
cation
interestingli
signi
fi
cant
baselin
vitamin
level
treatment
interact
observ
exacerb
rate
perform
post
hoc
analysi
subgroup
patient
de
fi
cient
vitamin
level
baselin
ngml
signi
fi
cant
reduct
number
exacerb
observ
intervent
group
one
six
copd
patient
trial
present
asymptomat
low
baselin
level
persist
entir
cours
studi
focu
futur
studi
import
subgroup
may
warrant
eventu
result
better
patienttailor
intervent
recent
frequent
exacerb
phenotyp
indenti
fi
ed
suggest
individu
therapyinclud
appropri
vitamin
substitutionmay
becom
import
also
assess
presenc
load
pathogen
bacteria
cultur
morn
sputa
trial
found
differ
erad
studi
arm
howev
monocyt
phagocytosi
capac
peripher
blood
monocyt
patient
receiv
vitamin
signi
fi
cantli
increas
compar
placebo
group
effect
pronounc
subgroup
lowest
baselin
level
therefor
tempt
specul
signi
fi
cant
reduct
exacerb
vitamin
de
fi
cient
subgroup
explain
import
upregul
impair
phagocytosi
capac
far
hard
evid
mechan
lack
final
note
lack
overal
effect
could
also
relat
local
vitamin
insensit
epigenet
modi
fi
cation
line
known
corticosteroid
resist
copd
recent
studi
cancer
shown
epigenet
silenc
key
enzym
vitamin
pathway
may
occur
leav
tumour
cell
insensit
vitamin
therapi
least
epigenet
modi
fi
cation
especi
context
smoke
poor
diet
may
explain
mani
observ
suggest
causal
relationship
vitamin
de
fi
cienci
fl
ammatori
diseas
whilst
supplement
later
diseas
revers
process
skelet
muscl
weak
common
moder
sever
copd
independ
predictor
respiratori
failur
death
although
underli
mechan
skelet
muscl
dysfunct
copd
entir
understood
gener
accept
combin
disus
respiratori
limit
elev
oxid
stress
system
fl
ammat
hypoxia
frequent
steroid
intak
main
caus
deterior
rehabilit
programm
copd
proven
success
still
larg
variabl
train
effect
sinc
muscl
weak
promin
featur
ricket
chronic
renal
failur
epidemiolog
studi
found
posit
associ
level
lower
extrem
function
older
person
vitamin
could
import
factor
muscl
health
elderli
individu
vitamin
statu
predict
physic
perform
consequ
declin
longterm
followup
sever
doubleblind
random
control
trial
demonstr
vitamin
supplement
increas
muscl
strength
balanc
reduc
risk
fall
elderli
although
recent
metaanalysi
look
effect
vitamin
supplement
muscl
strength
neg
posit
effect
still
found
de
fi
cient
patient
moreov
crosssect
analysi
nhane
indic
muscl
strength
continu
increas
throughout
serum
level
ngml
indic
obtain
bene
fi
cial
effect
muscl
higher
dose
supplement
might
necessari
patholog
level
adult
vitamin
de
fi
cienci
show
predominantli
type
ii
muscl
fi
bre
atrophi
sever
muscl
abnorm
enlarg
inter
fi
brillar
space
fi
ltration
fat
fi
brosi
glycogen
granul
convers
increas
rel
fi
bre
composit
type
ii
fi
bre
dimens
report
elderli
treatment
vitamin
type
ii
fi
bre
also
fi
rst
recruit
prevent
fall
may
explain
vitamin
supplement
shown
reduc
fall
copd
limb
muscl
adapt
lead
decreas
proport
slow
oxid
type
fi
bre
rel
increas
toward
glycolyt
type
ii
fi
bre
fi
bre
preferenti
affect
vitamin
de
fi
cienci
therefor
vitamin
de
fi
cienci
may
particular
concern
copd
patient
muscl
weak
dysfunct
exact
mechan
vitamin
affect
muscl
function
fulli
understood
howev
oh
may
impair
muscl
function
alter
calcium
regul
particular
oh
respons
activ
calcium
transport
sarcoplasm
reticulum
caatpas
known
regul
caatpas
phosphoryl
protein
sarcoplasm
reticulum
membran
increas
phosphat
transport
across
membran
interact
calmodulin
interestingli
calmodulin
highli
sensit
oxid
stress
typic
featur
copd
oh
may
yield
antioxid
properti
thu
vitamin
de
fi
cienci
increas
oxid
stress
eg
smoke
may
act
synergist
impair
calmodulin
function
muscl
structur
contractil
oh
also
import
role
protein
synthesi
muscl
cell
mediat
nuclear
receptormedi
gene
transcript
exampl
affect
actin
troponin
c
content
two
major
contractil
protein
skelet
muscl
may
upregul
gene
express
muscular
growth
factor
instanc
igfi
although
tempt
extrapol
vitamin
dmediat
action
skelet
muscl
healthi
elderli
subject
speci
fi
c
popul
copd
patient
still
shown
vitamin
de
fi
cienci
contribut
observ
muscl
weak
copd
present
direct
evid
causal
relationship
observ
vdr
genotyp
may
fl
uenc
quadricep
strength
copd
patient
line
assumpt
recent
data
also
show
vitamin
de
fi
cient
copd
patient
refer
rehabilit
higher
risk
dropout
reduc
bene
fi
walk
endur
post
hoc
analysi
moder
sever
copd
also
found
signi
fi
cant
effect
highdos
vitamin
supplement
top
month
rehabilit
term
improv
exercis
capac
therefor
random
control
trial
investig
supplement
vitamin
de
fi
cienci
may
posit
affect
muscl
forc
muscl
function
gener
copd
outcom
urgent
need
last
year
mani
clinic
studi
associ
low
vitamin
level
preval
incid
cancer
includ
lung
cancer
sever
studi
associ
vitamin
de
fi
cienci
autoimmun
diseas
like
type
diabet
multipl
sclerosi
rheumatoid
arthriti
de
fi
cient
vitamin
level
link
chronic
infect
tuberculosi
acut
viral
infect
like
fl
uenza
upper
tract
respiratori
infect
similar
data
also
avail
link
vitamin
de
fi
cienci
cardiovascular
diseas
arteri
hypertens
even
caus
mortal
beyond
scope
book
chapter
review
evid
vitamin
differ
chronic
diseas
strike
mani
current
consid
comorbid
condit
copd
accept
import
determin
copd
outcom
prognosi
tackl
vitamin
dmediat
effect
comorbid
condit
may
therefor
indirectli
improv
copd
statu
stress
howev
mention
relationship
vitamin
de
fi
cienci
differ
chronic
diseas
specul
often
reli
crosssect
retrospect
observ
evid
vitro
anim
research
human
placebocontrol
intervent
studi
observ
studi
prospect
longterm
followup
speci
fi
calli
design
demonstr
causal
relationship
often
lack
moreov
recent
intervent
studi
vitamin
supplement
multipl
sclerosi
diabet
fl
uenza
tuberculosi
report
disappoint
result
often
limit
statist
power
insuf
fi
cient
supplement
recent
expert
analysi
therefor
conclud
yet
insuf
fi
cient
evid
extracalcem
bene
fi
ts
vitamin
therapi
random
placebocontrol
intervent
trial
need
de
fi
ne
effect
copd
particular
intervent
studi
target
comorbid
condit
improv
copdspeci
fi
c
outcom
need
analog
ongo
trial
statin
copd
patient
wwwclinicaltrialsgov
one
may
think
larg
intervent
studi
vitamin
supplement
indirectli
directli
vitamin
also
believ
regul
extracellular
matrix
homeostasi
tissu
bone
within
particular
lung
skin
tissu
via
control
transform
growth
factorb
matrix
metalloproteinas
plasminogen
activ
system
compel
evid
vitamin
play
key
role
foetal
lung
growth
develop
matur
although
oh
toxic
klothonul
mice
result
phenotyp
skin
atrophi
osteoporosi
emphysema
recent
data
mice
show
sever
vitamin
de
fi
cienci
earli
life
also
result
impair
lung
function
differ
lung
volum
growth
evid
human
epidemiolog
studi
also
suggest
higher
prenat
uptak
vitamin
protect
childhood
wheez
impair
lung
growth
childhood
asthma
known
risk
factor
copd
later
age
causal
link
vitamin
de
fi
cienci
copd
may
therefor
alreadi
exist
earli
childhood
recent
evid
anim
studi
corrobor
idea
vdr
knockout
mice
develop
emphysemat
airspac
enlarg
associ
upregul
matrix
metalloproteinas
lung
increas
fl
ux
fl
ammatori
cell
develop
typic
lymphoid
aggreg
around
peripher
airway
evid
vitamin
pathway
play
pivot
role
biolog
healthi
diseas
lung
compel
mani
chronic
diseas
vitamin
de
fi
cienci
highli
preval
copd
occur
frequent
increas
diseas
sever
de
fi
cienci
may
enhanc
local
airway
fl
ammat
may
also
induc
acceler
ongo
comorbid
diseas
subsequ
impair
gener
prognosi
diseas
fig
far
hard
evid
causal
role
vitamin
de
fi
cienci
pathogenesi
copdrel
osteoporosi
extracalcem
effect
recent
random
control
trial
demonstr
overal
effect
highdos
supplement
exacerb
support
import
effect
limit
subgroup
patient
highli
de
fi
cient
vitamin
embark
new
intervent
trial
vitamin
copd
target
subgroup
fundament
research
need
learn
vitamin
de
fi
cienci
interact
smoke
develop
copd
abl
understand
far
intervent
trial
vitamin
fail
yield
import
health
bene
fi
ts
chronic
diseas
includ
copd
